FCGR3B and sarcoma: We observed a significant increase of CD16+ cells interacting with sarcoma cells when treated with NKG2D-CD16 in three independent experiments and two different cell lines (RD-ES: p<0.0001, SW1353: p<0.0001, Figures 3A, S2A).